Recent News

• 05.12.2026 - Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
• 05.04.2026 - Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
• 04.29.2026 - Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
• 04.20.2026 - Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
• 04.16.2026 - Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
• 04.16.2026 - Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Recent Filings

• 05.04.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 05.04.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 04.29.2026 - D Notice of Exempt Offering of Securities
• 04.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.22.2026 - 4 Statement of changes in beneficial ownership of securities